Activation of peroxisome proliferator-activated receptor-δ as novel therapeutic strategy to prevent in-stent restenosis and stent thrombosis


  • J. Hytönen
  • O. Leppänen
  • J.H. Braesen
  • W.H. Schunck
  • D. Mueller
  • F. Jung
  • C. Mrowietz
  • M. Jastroch
  • M. von Bergwelt-Baildon
  • K. Kappert
  • A. Heuser
  • J.D. Drenckhahn
  • B. Pieske
  • L. Thierfelder
  • S. Ylä-Herttuala
  • F. Blaschke


  • Arteriosclerosis Thrombosis and Vascular Biology


  • Arterioscler Thromb Vasc Biol 36 (8): 1534-1548


  • OBJECTIVE: Drug-eluting coronary stents reduce restenosis rate and late lumen loss compared with bare-metal stents; however, drug-eluting coronary stents may delay vascular healing and increase late stent thrombosis. The peroxisome proliferator-activated receptor-delta (PPARdelta) exhibits actions that could favorably influence outcomes after drug-eluting coronary stents placement. APPROACH AND RESULTS: Here, we report that PPARdelta ligand-coated stents strongly reduce the development of neointima and luminal narrowing in a rabbit model of experimental atherosclerosis. Inhibition of inflammatory gene expression and vascular smooth muscle cell (VSMC) proliferation and migration, prevention of thrombocyte activation and aggregation, and proproliferative effects on endothelial cells were identified as key mechanisms for the prevention of restenosis. Using normal and PPARdelta-depleted VSMCs, we show that the observed effects of PPARdelta ligand GW0742 on VSMCs and thrombocytes are PPARdelta receptor dependent. PPARdelta ligand treatment induces expression of pyruvate dehydrogenase kinase isozyme 4 and downregulates the glucose transporter 1 in VSMCs, thus impairing the ability of VSMCs to provide the increased energy demands required for growth factor-stimulated proliferation and migration. CONCLUSIONS: In contrast to commonly used drugs for stent coating, PPARdelta ligands not only inhibit inflammatory response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. Thus, pharmacological PPARdelta activation could be a promising novel strategy to improve drug-eluting coronary stents outcomes.